Advertisement
Advertisement
U.S. markets close in 1 hour 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5700-0.0150 (-2.56%)
As of 02:04PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.5850
Open0.5900
Bid0.5700 x 900
Ask0.5848 x 1200
Day's Range0.5700 - 0.6000
52 Week Range0.5600 - 2.0400
Volume31,011
Avg. Volume70,000
Market Cap25.814M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.4580
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Acasti Pharma, Inc.
    Analyst Report: Boston Scientific CorporationBoston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
Advertisement
Advertisement